DK0944397T3 - Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer - Google Patents

Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer

Info

Publication number
DK0944397T3
DK0944397T3 DK97905539T DK97905539T DK0944397T3 DK 0944397 T3 DK0944397 T3 DK 0944397T3 DK 97905539 T DK97905539 T DK 97905539T DK 97905539 T DK97905539 T DK 97905539T DK 0944397 T3 DK0944397 T3 DK 0944397T3
Authority
DK
Denmark
Prior art keywords
iscom
receptor molecules
antigenic substances
pct
matrix containing
Prior art date
Application number
DK97905539T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Jill Ekstroem
Original Assignee
Bengtsson Karin Loevgren
Jill Ekstroem
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bengtsson Karin Loevgren, Jill Ekstroem, Bror Morein filed Critical Bengtsson Karin Loevgren
Application granted granted Critical
Publication of DK0944397T3 publication Critical patent/DK0944397T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK97905539T 1996-02-21 1997-02-20 Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer DK0944397T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600648A SE9600648D0 (sv) 1996-02-21 1996-02-21 Receptorbimdande enhet
PCT/SE1997/000287 WO1997030726A1 (en) 1996-02-21 1997-02-20 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances

Publications (1)

Publication Number Publication Date
DK0944397T3 true DK0944397T3 (da) 2004-06-01

Family

ID=20401482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905539T DK0944397T3 (da) 1996-02-21 1997-02-20 Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer

Country Status (12)

Country Link
US (1) US6027732A (da)
EP (1) EP0944397B1 (da)
AT (1) ATE258066T1 (da)
AU (1) AU718443B2 (da)
BR (1) BR9707638A (da)
CA (1) CA2247103C (da)
DE (1) DE69727314T2 (da)
DK (1) DK0944397T3 (da)
ES (1) ES2214608T3 (da)
NZ (1) NZ331418A (da)
SE (1) SE9600648D0 (da)
WO (1) WO1997030726A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7776343B1 (en) * 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
JP2003514872A (ja) * 1999-11-19 2003-04-22 シーエスエル、リミテッド ワクチン組成物
SE0003538D0 (sv) * 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
ATE361097T1 (de) * 2002-01-15 2007-05-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp
US20040235770A1 (en) * 2003-04-02 2004-11-25 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
EP1781325A2 (en) * 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403081A1 (fr) * 1977-09-19 1979-04-13 Merieux Inst Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.

Also Published As

Publication number Publication date
CA2247103C (en) 2009-01-20
BR9707638A (pt) 2000-01-04
US6027732A (en) 2000-02-22
DE69727314D1 (de) 2004-02-26
NZ331418A (en) 2000-03-27
WO1997030726A1 (en) 1997-08-28
AU2238397A (en) 1997-09-10
CA2247103A1 (en) 1997-08-28
DE69727314T2 (de) 2004-11-18
AU718443B2 (en) 2000-04-13
ATE258066T1 (de) 2004-02-15
SE9600648D0 (sv) 1996-02-21
EP0944397A1 (en) 1999-09-29
EP0944397B1 (en) 2004-01-21
ES2214608T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
DK0944397T3 (da) Iscom eller iscom-matrix indeholdende hydrofobe receptormolekyler til antigene stoffer
AU6253898A (en) Use of microparticles combined with submicron oil-in-water emulsions
WO2006026389A3 (en) Ceramide derivatives as modulators of immunity and autoimmunity
AU6105398A (en) Antisun composition containing a solid elastomeric organopolysiloxane
AR087617A2 (es) Panel compuesto de arundo donax y metodo para elaborarlo
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
DK0993831T3 (da) Forbindelser og præparater til tilförsel af aktive stoffer
MY132623A (en) Method for producing superheavy oil emulsion fuel and fuel produced thereby
GB0016918D0 (en) Method of providing an image on a substrate, and an ink for use therein
ATE389397T1 (de) Adjuvante zusammensetzungen
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.
DE69120942D1 (de) Hilfsstoffzusammensetzungen in fester form, dispergieren in wässerigen medien
ES2196150T3 (es) Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion.
ES2187072T3 (es) Formulacion cosmetica estable a la luz que contiene butilmetoxi-dibenzoilmetano.
DK0865271T3 (da) Stabiliserede solbeskyttelsespræparater
DK0745168T3 (da) Udfyldningssystem til vægge og paneler i bygninger
Hübscher et al. Bundesdeutsche Arbeitsgemeinschaft für Veränderliche Sterne eV (BAV): Beobachtungsergebnisse.
IL114141A0 (en) Method for preparing cloud stable extract
ATE145191T1 (de) Azofarbstoffe enthaltende molekularsiebe
ES2177321T3 (es) Composiciones cosmeticas que comprende un tensioactivo anionico de alquilpoliglicosido, una goma de galactomanano y sus utilizaciones.
UA29496C2 (uk) Ротор для перемішуючих пристроїв
Garcia Vargas et al. VizieR Online Data Catalog: Emission lines from giant HII regions (Garcia Vargas+, 1995)
Zhao et al. VizieR Online Data Catalog: Tables of membership for 43 open clusters (Zhao+, 1995)
EP0873136A4 (en) HIGH FLUORESCENCE SPECIFIC IMMUNITY BUILDING FACTOR AND METHODS OF USE
Hopp et al. VizieR Online Data Catalog: CCD photometry of 11 dwarf irregular galaxies (Hopp+, 1995)